Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel
Aim The primary objective of this review is to develop a practice-based expert group opinion on the role of precision medicine with a specific focus on sulfonylureas (SUs) in diabetes management. Background The clinical etiology, presentation and complications of diabetes vary from one patient to another, making the management of the disease challenging. The pre-eminent feature of diabetes mellitus (DM) are chronically elevated blood glucose concentrations; however, in clinical practice, the exclusion of autoimmunity, pregnancy, pancreatic disease or injury and rare genetic forms of diabetes is crucial. Within this framework, precision medicine provides unique insights into the risk factors and natural history of DM. Precision medicine goes beyond genomics and encompasses patient-centered care, molecular technologies and data sharing. Precision medicine has evolved in the field of diabetology. It has helped improve the efficacy of SUs, a class of drugs, which have been effectively used in the management of diabetes mellitus for decades, and it has enabled the expansion of SUs use in diabetes patients with genetic mutations. Review Results After due discussions, the expert group analyzed studies that focused on the use of SUs in diabetes patients with genomic variations and rare mutations. The expert group opined that SUs are important glucose-lowering drugs and that precision medicine helps in improving the efficacy of SUs by matching them to those patients who will benefit most. Conclusion Precision medicine opens new vistas for the effective use of SUs in unexpected patient populations, such as those with genetic mutations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Diabetes therapy - 11(2020), 2 vom: 08. Jan., Seite 411-422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kalra, Sanjay [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Genetic polymorphisms |
|---|
| Anmerkungen: |
© The Author(s) 2020 |
|---|
| doi: |
10.1007/s13300-019-00753-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2097495184 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2097495184 | ||
| 003 | DE-627 | ||
| 005 | 20240402081049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230401s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13300-019-00753-5 |2 doi | |
| 035 | |a (DE-627)OLC2097495184 | ||
| 035 | |a (DE-He213)s13300-019-00753-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kalra, Sanjay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2020 | ||
| 520 | |a Aim The primary objective of this review is to develop a practice-based expert group opinion on the role of precision medicine with a specific focus on sulfonylureas (SUs) in diabetes management. Background The clinical etiology, presentation and complications of diabetes vary from one patient to another, making the management of the disease challenging. The pre-eminent feature of diabetes mellitus (DM) are chronically elevated blood glucose concentrations; however, in clinical practice, the exclusion of autoimmunity, pregnancy, pancreatic disease or injury and rare genetic forms of diabetes is crucial. Within this framework, precision medicine provides unique insights into the risk factors and natural history of DM. Precision medicine goes beyond genomics and encompasses patient-centered care, molecular technologies and data sharing. Precision medicine has evolved in the field of diabetology. It has helped improve the efficacy of SUs, a class of drugs, which have been effectively used in the management of diabetes mellitus for decades, and it has enabled the expansion of SUs use in diabetes patients with genetic mutations. Review Results After due discussions, the expert group analyzed studies that focused on the use of SUs in diabetes patients with genomic variations and rare mutations. The expert group opined that SUs are important glucose-lowering drugs and that precision medicine helps in improving the efficacy of SUs by matching them to those patients who will benefit most. Conclusion Precision medicine opens new vistas for the effective use of SUs in unexpected patient populations, such as those with genetic mutations. | ||
| 650 | 4 | |a Genetic polymorphisms | |
| 650 | 4 | |a Monogenic diabetes | |
| 650 | 4 | |a Precision medicine | |
| 650 | 4 | |a Sulfonylureas | |
| 700 | 1 | |a Das, A. K. |4 aut | |
| 700 | 1 | |a Bajaj, Sarita |4 aut | |
| 700 | 1 | |a Priya, Gagan |4 aut | |
| 700 | 1 | |a Ghosh, Sujoy |4 aut | |
| 700 | 1 | |a Mehrotra, R. N. |4 aut | |
| 700 | 1 | |a Das, Sambit |4 aut | |
| 700 | 1 | |a Shah, Parag |4 aut | |
| 700 | 1 | |a Deshmukh, Vaishali |4 aut | |
| 700 | 1 | |a Sanyal, Debmalya |4 aut | |
| 700 | 1 | |a Chandrasekaran, Sruti |4 aut | |
| 700 | 1 | |a Khandelwal, Deepak |4 aut | |
| 700 | 1 | |a Joshi, Amaya |4 aut | |
| 700 | 1 | |a Nair, Tiny |4 aut | |
| 700 | 1 | |a Eliana, Fatimah |4 aut | |
| 700 | 1 | |a Permana, Hikmat |4 aut | |
| 700 | 1 | |a Fariduddin, M. D. |4 aut | |
| 700 | 1 | |a Shrestha, Pradeep Krishna |4 aut | |
| 700 | 1 | |a Shrestha, Dina |4 aut | |
| 700 | 1 | |a Kahandawa, Shayaminda |4 aut | |
| 700 | 1 | |a Sumanathilaka, Manilka |4 aut | |
| 700 | 1 | |a Shaheed, Ahamed |4 aut | |
| 700 | 1 | |a Rahim, Aly Ahmed Abdel |4 aut | |
| 700 | 1 | |a Orabi, Abbas |4 aut | |
| 700 | 1 | |a Al-ani, Ahmed |4 aut | |
| 700 | 1 | |a Hussein, Wiam |4 aut | |
| 700 | 1 | |a Kumar, Dinesh |4 aut | |
| 700 | 1 | |a Shaikh, Khalid |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes therapy |d Springer Healthcare, 2010 |g 11(2020), 2 vom: 08. Jan., Seite 411-422 |h Online-Ressource |w (DE-627)632439165 |w (DE-600)2566702-6 |w (DE-576)329830902 |x 1869-6961 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:2 |g day:08 |g month:01 |g pages:411-422 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13300-019-00753-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 2 |b 08 |c 01 |h 411-422 | ||